Table 2.
ANAs and anti-cytoplasmic antibodies on HEp-2 cells in BC and non-cancer control sera
| IFA pattern [%]* | Convenience control female | Osteoarthritis control female | Benign breast disease | Ductal carcinoma in situ | Invasive carcinoma |
|---|---|---|---|---|---|
| Homogeneous | 6 | 7 | 46 | 41 | 29 |
| Speckled | 7 | 11 | 8 | 17 | 38 |
| Anti-nucleolar | 2 | 3 | 30 | 27 | 32 |
| Anti-centromere | 0 | 0 | 2 | 5 | 5 |
| Anti-centrosome | 0 | 0 | 16 | 18 | 12** |
| Anti-mitochondrial | 0 | 0 | 10 | 11 | 22 |
| Multiple nuclear dots | 0 | 0 | 3 | 3 | 5 |
| Cytoskeletal | 0 | 0 | 0 | 3 | 3 |
| Mixed pattern | 2 | 9 | 37 | 45 | 51 |
| Other | 0 | 1 | 3 | 5 | 4 |
*Percent of individual patterns do not add up to 100% due to high frequency of mixed patterns.
**Percent likely underestimates prevalence of anti-centrosome antibodies because of the masking effect of the high frequency of cytoplasmic speckles and heavy mitochondrial fluorescence in sera from invasive breast carcinoma.